Commentary on “New directions for frontotemporal dementia drug discovery.” Do we know enough to develop meaningful treatments for frontotemporal dementia?

References 

1. Trojanowski JQ, Duff K, Filit H, Korshetz W, Kuret J, Murphy D, et al. New directions for frontotemporal dementia drug discovery. Alzheimer’s & Dementia. 2008;4:89–93
2. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord. 2005;19(Suppl 1):S3–S6
   • CrossRef
3. Van Deerlin VM, Wood EM, Moore P, Yuan W, Forman MS, Clark CM, et al. Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol. 2007;64:1148–1153
   • CrossRef
4. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl). 2007;114:5–22Epub June 20, 2007
5. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci. 2005;25:10637–10647
   • CrossRef
6. Huey ED, Putnam KT, Gafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22
   • CrossRef
7. Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A. 2006;103:9673–9678Epub June 12, 2006
   • MEDLINE
   • CrossRef
8. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science. 2007;316:750–754
   • CrossRef